

## Referenties bij MAGMA 2-2012

### ZUURREMMENDE THERAPIE BIJ BARRETT (pag. 36–37)

1. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. *Gastroenterology* 2011; 140:1084–1091.
2. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology* 2011; 140:e18–e52.
3. Bremner CG, Lynch VP, Ellis FH Jr. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. *Surgery* 1970; 68:209–16.
4. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy. *Arch Surg* 1983; 118:543–49.
5. Dvorak K, Payne CM, Chavarria M, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. *Gut* 2007; 56: 763–71.
6. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. *Gastroenterology* 1996; 111: 1192–99.
7. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Gastric surgery is not a risk for Barrett's esophagus or esophageal adenocarcinoma. *Gastroenterology* 2001; 121: 1281–85.
8. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. *Am J Gastroenterol*. 2003 Dec;98(12):2616-20.
9. Miehlke S, Madisch A, Kirsch C, et al. Intra-gastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. *Aliment Pharmacol Ther* 2005; 21: 963-976
10. de Bortoli N, Martinucci I, Piaggi P, et al. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year. *Aliment Pharmacol Ther*. 2011 May;33(9):1019-27.
11. Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. *Cochrane Database Syst Rev*. 2009 Oct 7(4):CD004275.
12. Hameeteman W, v d Boomgaard DM, Dekker W, Schrijver M, Wesdorp IC, Tytgat GN. Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study. *J Clin Gastroenterol*. 1987 Aug;9(4):390-4.
13. Herrera JL, Shay SS, McCabe M, Peura DA, Johnson LF. Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. *Am J Gastroenterol*. 1990 Oct;85(10):1335-8.
14. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. *Clin Gastroenterol Hepatol*. 2010 Jan;8(1):23-9. Epub 2009 Aug 11.
15. Herrero LA, van Vilsteren FG, Pouw RE, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. *Gastrointest Endosc*. 2011 Apr;73(4):682-90. Epub 2011 Feb 2.

### **Vraag en aanbod endoscopie in tijdperk darmkankerscreening (pag. 43)**

1. Terhaar Sive Droste JS, Craanen ME, Kolkman JJ, Mulder CJ. Dutch endoscopic capacity in the era of colorectal cancer screening. *Neth. J. Med.* 2006;64:371-373.
2. Health Council of the Netherlands. *A national colorectal cancer screening programme*. 2009. The Hague. Ref Type: Report
3. Kolkman JJ, Mulder CJ. The nature of the Dutch endoscopic practice in 1999. *MAGMA* 2000;6. Ref Type: Magazine Article
4. S.T. van Turenhout, J.S. Terhaar sive Droste, G.A. Meijer, A.A. Masclee, C.J.J. Mulder. Anticipating implementation of colorectal cancer screening in The Netherlands: a nationwide survey on endoscopic supply and demand. *BMC Cancer* 2012;Jan 26;12(1):46. [Epub ahead of print]
5. Statistics Netherlands. *Dutch population according to age, gender and region 2009*. Statistics Netherlands. 2010. Ref Type: Electronic Citation.

### **CASUÏSTIEK – De afvallende aannemer (pag. 61)**

1. Stone JH, et al. *N Engl J Med* 2012;366:539-51.
2. Hamano H, et al. *N Engl J Med* 2001;344:732-8.
3. Sah RP, et al. *Gastroenterology* 2010;139:140-8; quiz e12-3.
4. Ghazale A, et al. *Gastroenterology* 2008;134:706-15.
5. Kamisawa T, et al. *J Gastroenterol* 2003;38:982-4.
6. Maillette de Buy Wenniger L, et al. *Endoscopy* 2012;44:66-73.
7. Aoki S, et al. *Histopathology* 2005;47:147-58.
8. van der Neut Kolfschoten M, et al. *Science* 2007;317:1554-7.
9. Zen Y, et al. *Hepatology* 2007;45:1538-46.

### **CASUÏSTIEK – Sumatriptan-geïnduceerde darmischemie (pag. 61-62)**

1. Moawad FJ, Goldkind L. An unusual case of colonic ischemia. *South. Med. J.* 2009 Apr.;102(4):405-407.
2. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. *Hum. Pathol.* 2007 Apr.;38(4):527-536.
3. Liu JJ, Ardolf JC. Sumatriptan-associated mesenteric ischemia. *Ann. Intern. Med.* 2000 Apr. 4;132(7):597.
4. Knudsen JF, Friedman B, Chen M, Goldwasser JE. Ischemic colitis and sumatriptan use. *Arch. Intern. Med.* 1998 Sep. 28;158(17):1946-1948.
5. Bateman DN. Triptans and migraine. *Lancet.* 2000 Mar. 11;355(9207):860-861.
6. Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. *Lancet.* 2009 Oct. 31;374(9700):1501-1502.
7. Allen C, Dayno J. Tolerability of sumatriptan: clinical trials and postmarketing experience. *Cephalalgia.* 2001 Oct.;21(8):855-856.

### **CASUÏSTIEK – Waar komt hepatitis vandaan? (pag. 63)**

1. Kamar N, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med* 2008;358:811-817.
2. Aggarwal R, Jameel S. Hepatitis E. *Hepatology* 2011;54:2218-2226.
3. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. *J Hepatol* 2008;48:494-503.
4. Purcell RH, Emerson SU. Hidden danger: the raw facts about hepatitis E virus. *J Infect Dis* 2010;202:819-821.
5. Kamar N, et al. *Gastroenterology* 2010;139:1612-1618.
6. Haagsma EB, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. *Liver Transpl* 2010;16:474-477.
7. Shrestha MP, et al. Safety and efficacy of a recombinant hepatitis E vaccine. *N Engl J Med* 2007;356:895-903.
8. Zhu FC, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *Lancet* 2010;376:895-902.